Nova Anchora has raised $23.0M to develop a corrective topical treatment for Dystrophic Epidermolysis Bullosa (DEB), a genetic skin condition that currently has no cure. The funding will support the company's work on the therapy.

Get the full Nova Anchora company profile
Access contacts, investors, buying signals & more
Nova Anchora has raised $23.0M to develop a corrective topical treatment for Dystrophic Epidermolysis Bullosa (DEB), a genetic skin condition that currently has no cure. The funding will support the company's work on the therapy.
📢 Chai Discovery has partnered with Roche to provide its AI-driven molecular design platform and Chai-3 model for drug discovery. Roche will leverage this technology to accelerate research strategies and protein-based therapeutic programs across its therapeutic areas.
Specific financial terms of the collaboration were not disclosed by the parties. 🔗 Read more https://lnkd.in/gMQBbj4s 💡 Other Biopharma Highlights [Deals] • 11/05 Chai Discovery partners with Roche to apply AI platform across multiple drug discovery programs [Funding] • 11/05 Alethio Therapeutics raises $90 million in Series A to advance G6B-targeting therapy through Phase 1/2a in essential th

Whelix
Whelix is building the physical validation layer for AI-driven biology, starting with intelligent robotic systems that automate mammalian cell culture end-to-end. As AI accelerates discovery in the digital world, every new hypothesis, molecule, and therapy still needs to be validated in living cells. Cell culture remains one of the most manual, variable, and failure-prone workflows across drug discovery, cell therapy, and biomanufacturing. Our platforms combine purpose-built hardware, computer vision, digital twin simulation, and agentic software to automate incubation, liquid handling, imaging, protocol execution, and cell monitoring. By turning cell culture into reproducible, 24/7 lab infrastructure, Whelix helps scientists run more experiments, generate more consistent biology, and accelerate the path from in silico design to living-cell validation.
$5.4M Unknown
today

Recursive
Recursive self-improving superintelligence to automate knowledge discovery.
$650.0M Series a
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 | ![]() NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Unknown round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Feldwerke Germany | Unknown | $13.5M | today |
| 2 | ![]() Clínica Experts Brazil | Unknown | $910.9K | today |
today
| $7.2B |
| 2y ago |
| 3 | ![]() GRAIL United States | Unknown | $7.1B | 2y ago |
| 4 | ![]() Illumina United States | Unknown | $7.1B | 2y ago |
| 5 | ![]() RemeGen Biosciences United States | Grant | $5.6B | 9mo ago |
| 3 |
![]() Afreenergy Solar Mauritius |
| Unknown |
| $13.4M |
| today |
| 4 | ![]() KA-YO Sweden | Unknown | $819.7K | today |
| 5 | ![]() skilder.ai Switzerland | Unknown | $49.0K | today |
Trusted by 200+ sales teams
See who invested in Nova Anchora and reach their contacts directly.
Start free trial
Mirava
Recently received

Luquos Energy
Recently received

Vensum Power
Recently received